{"id":69170,"date":"2026-07-01T14:01:10","date_gmt":"2026-07-01T06:01:10","guid":{"rendered":"https:\/\/flcube.com\/?p=69170"},"modified":"2026-07-01T14:01:11","modified_gmt":"2026-07-01T06:01:11","slug":"roche-receives-fda-priority-review-for-enspryng-in-thyroid-eye-disease-il-6-inhibitor-leverages-novel-recycling-technology-for-second-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69170","title":{"rendered":"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced today that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted and granted <strong>Priority Review<\/strong> to a <strong>supplemental Biologics License Application (sBLA)<\/strong> for <strong>Enspryng\u00ae (satralizumab)<\/strong> for the treatment of <strong>thyroid eye disease (TED)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Developed by <strong>Chugai Pharmaceutical Co., Ltd.<\/strong>, a member of the Roche Group, Enspryng represents a potential expansion of the first and only <strong>IL-6 receptor inhibitor<\/strong> currently approved in approximately <strong>90 countries and regions<\/strong> for <strong>neuromyelitis optica spectrum disorder (NMOSD)<\/strong>, with an established safety profile across more than <strong>10,000 patients<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplemental Biologics License Application (sBLA)<\/td><\/tr><tr><td><strong>Review Designation<\/strong><\/td><td>Priority Review<\/td><\/tr><tr><td><strong>Review Timeline<\/strong><\/td><td>6 months (target action date: Q4 2026)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Enspryng (satralizumab)<\/td><\/tr><tr><td><strong>Proposed Indication<\/strong><\/td><td>Thyroid eye disease (TED)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Chugai Pharmaceutical Co., Ltd. (Roche Group)<\/td><\/tr><tr><td><strong>Current Approvals<\/strong><\/td><td>NMOSD in ~90 countries\/regions including US and EU<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-background-amp-unmet-need\" class=\"wp-block-heading\">Disease Background &amp; Unmet Need<\/h2>\n\n\n\n<h3 id=\"h-thyroid-eye-disease-ted\" class=\"wp-block-heading\">Thyroid Eye Disease (TED)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pathophysiology:<\/strong> Autoimmune inflammatory disorder affecting orbital tissues, driven by <strong>IL-6-mediated inflammation<\/strong><\/li>\n\n\n\n<li><strong>Clinical Manifestations:<\/strong> Proptosis (eye bulging), diplopia (double vision), periorbital edema, and potential vision loss<\/li>\n\n\n\n<li><strong>Patient Burden:<\/strong> Significant impact on quality of life, appearance, and visual function<\/li>\n\n\n\n<li><strong>Current Treatment Landscape:<\/strong><\/li>\n\n\n\n<li><strong>First-line:<\/strong> High-dose corticosteroids (limited efficacy, significant toxicity)<\/li>\n\n\n\n<li><strong>Second-line:<\/strong> Orbital radiation (variable response, long-term risks)<\/li>\n\n\n\n<li><strong>Surgical interventions:<\/strong> Reserved for severe cases with permanent structural changes<\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> Critical need for targeted biologic therapies addressing underlying inflammatory mechanisms<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-il-6-as-therapeutic-target\" class=\"wp-block-heading\">IL-6 as Therapeutic Target<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Key Cytokine:<\/strong> Interleukin-6 (IL-6) serves as central mediator in TED pathogenesis<\/li>\n\n\n\n<li><strong>Inflammatory Cascade:<\/strong> IL-6 drives fibroblast activation, glycosaminoglycan production, and orbital tissue expansion<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Targeted IL-6 inhibition offers precision approach to modulate disease-specific inflammation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-enspryng-novel-recycling-antibody-technology\" class=\"wp-block-heading\">Enspryng: Novel Recycling Antibody Technology<\/h2>\n\n\n\n<h3 id=\"h-molecular-innovation\" class=\"wp-block-heading\">Molecular Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Humanized monoclonal antibody targeting IL-6 receptor activity<\/li>\n\n\n\n<li><strong>Core Technology:<\/strong> <strong>Novel recycling antibody platform<\/strong> enabling:<\/li>\n\n\n\n<li><strong>Strong binding affinity<\/strong> to IL-6 receptor<\/li>\n\n\n\n<li><strong>Repeated receptor engagement<\/strong> through intracellular recycling mechanism<\/li>\n\n\n\n<li><strong>Sustained target inhibition<\/strong> with lower dosing frequency vs. conventional antibodies<\/li>\n\n\n\n<li><strong>Mechanism Advantage:<\/strong> Rapid and sustained suppression of inflammatory pathways through enhanced pharmacokinetic\/pharmacodynamic profile<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-differentiation\" class=\"wp-block-heading\">Clinical Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Proven Safety:<\/strong> Well-established profile from NMOSD experience (>10,000 patients)<\/li>\n\n\n\n<li><strong>Dosing Convenience:<\/strong> Subcutaneous administration with optimized frequency<\/li>\n\n\n\n<li><strong>Target Specificity:<\/strong> Selective IL-6 pathway inhibition minimizing off-target effects<\/li>\n\n\n\n<li><strong>Therapeutic Breadth:<\/strong> Potential first IL-6 inhibitor specifically approved for TED<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-ted-market-dynamics\" class=\"wp-block-heading\">TED Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> Estimated <strong>16\u201319 cases per 100,000 population<\/strong> in the US<\/li>\n\n\n\n<li><strong>Addressable Population:<\/strong> Approximately <strong>40,000\u201350,000 active TED patients<\/strong> requiring treatment<\/li>\n\n\n\n<li><strong>Premium Pricing Environment:<\/strong> Orphan disease designation supports high-value pricing<\/li>\n\n\n\n<li><strong>Reimbursement Landscape:<\/strong> Favorable coverage for targeted biologics in autoimmune conditions<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Potential:<\/strong> Could become <strong>first approved IL-6 inhibitor<\/strong> for TED indication<\/li>\n\n\n\n<li><strong>Differentiation vs. Teprotumumab:<\/strong> Alternative mechanism of action (IGF-1R vs. IL-6R) offering treatment options for non-responders<\/li>\n\n\n\n<li><strong>Portfolio Synergy:<\/strong> Leverages existing Enspryng commercial infrastructure and physician relationships<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Success in US could accelerate regulatory filings in other major markets<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-implications-for-roche\" class=\"wp-block-heading\">Commercial Implications for Roche<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Upside:<\/strong> Peak annual sales potential of <strong>USD 300\u2013500 million<\/strong> in TED indication<\/li>\n\n\n\n<li><strong>Franchise Extension:<\/strong> Expands Enspryng&#8217;s therapeutic footprint beyond rare neuroimmunological disorders<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens Roche&#8217;s position in ophthalmology and autoimmune disease portfolios<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> Orphan drug status and novel mechanism support premium reimbursement<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-strategy-amp-next-steps\" class=\"wp-block-heading\">Development Strategy &amp; Next Steps<\/h2>\n\n\n\n<h3 id=\"h-regulatory-pathway\" class=\"wp-block-heading\">Regulatory Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Priority Review Benefits:<\/strong> Accelerated 6-month review timeline vs. standard 10-month process<\/li>\n\n\n\n<li><strong>Target Approval:<\/strong> Q4 2026 based on current FDA scheduling<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Potential parallel filings in EU, Japan, and other key markets following US decision<\/li>\n\n\n\n<li><strong>Label Expansion:<\/strong> Success could support additional autoimmune ophthalmology indications<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-evidence-requirements\" class=\"wp-block-heading\">Clinical Evidence Requirements<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoints:<\/strong> Likely focused on proptosis reduction, clinical activity score improvement, and quality of life measures<\/li>\n\n\n\n<li><strong>Safety Database:<\/strong> Leveraging extensive NMOSD safety experience to support favorable risk-benefit profile<\/li>\n\n\n\n<li><strong>Comparative Data:<\/strong> Potential head-to-head studies vs. existing TED therapies in post-marketing commitments<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-considerations\" class=\"wp-block-heading\">Investment Considerations<\/h2>\n\n\n\n<h3 id=\"h-success-catalysts\" class=\"wp-block-heading\">Success Catalysts<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strong Efficacy Data:<\/strong> Demonstrated superiority over current standard of care<\/li>\n\n\n\n<li><strong>Favorable Safety Profile:<\/strong> Clean safety signal supporting broad patient eligibility<\/li>\n\n\n\n<li><strong>Physician Adoption:<\/strong> Effective education programs highlighting IL-6 pathway rationale<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Streamlined reimbursement and distribution channels<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-risk-factors\" class=\"wp-block-heading\">Risk Factors<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Uncertainty:<\/strong> Priority Review doesn&#8217;t guarantee approval<\/li>\n\n\n\n<li><strong>Competitive Pressure:<\/strong> Existing TED therapies with established market presence<\/li>\n\n\n\n<li><strong>Pricing Scrutiny:<\/strong> High-cost biologics facing increasing payer scrutiny<\/li>\n\n\n\n<li><strong>Market Size Limitations:<\/strong> Orphan indication with finite addressable population<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory review, market opportunities, and commercial expectations. Actual outcomes may differ due to risks including FDA decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69171,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[38,44,940,163,939],"class_list":["post-69170","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-approval-filings","tag-ophthalmology","tag-otcmkts-rhhby","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng\u00ae (satralizumab) for the treatment of thyroid eye disease (TED).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69170\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication\" \/>\n<meta property=\"og:description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng\u00ae (satralizumab) for the treatment of thyroid eye disease (TED).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69170\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-01T06:01:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-01T06:01:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication\",\"datePublished\":\"2026-07-01T06:01:10+00:00\",\"dateModified\":\"2026-07-01T06:01:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170\"},\"wordCount\":737,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0104.webp\",\"keywords\":[\"Market approval filings\",\"Ophthalmology\",\"OTCMKTS: RHHBY\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69170#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69170\",\"name\":\"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0104.webp\",\"datePublished\":\"2026-07-01T06:01:10+00:00\",\"dateModified\":\"2026-07-01T06:01:11+00:00\",\"description\":\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng\u00ae (satralizumab) for the treatment of thyroid eye disease (TED).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69170\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69170#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication - Insight, China&#039;s Pharmaceutical Industry","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng\u00ae (satralizumab) for the treatment of thyroid eye disease (TED).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69170","og_locale":"en_US","og_type":"article","og_title":"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication","og_description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng\u00ae (satralizumab) for the treatment of thyroid eye disease (TED).","og_url":"https:\/\/flcube.com\/?p=69170","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-01T06:01:10+00:00","article_modified_time":"2026-07-01T06:01:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69170#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69170"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication","datePublished":"2026-07-01T06:01:10+00:00","dateModified":"2026-07-01T06:01:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69170"},"wordCount":737,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69170#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0104.webp","keywords":["Market approval filings","Ophthalmology","OTCMKTS: RHHBY","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69170#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69170","url":"https:\/\/flcube.com\/?p=69170","name":"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69170#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69170#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0104.webp","datePublished":"2026-07-01T06:01:10+00:00","dateModified":"2026-07-01T06:01:11+00:00","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng\u00ae (satralizumab) for the treatment of thyroid eye disease (TED).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69170#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69170"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69170#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0104.webp","width":1080,"height":608,"caption":"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69170#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease \u2013 IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69170"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69170\/revisions"}],"predecessor-version":[{"id":69172,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69170\/revisions\/69172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69171"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}